Mon, Dec 22, 2014, 6:14 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Sarepta Therapeutics, Inc. Message Board

  • niwrad1809 niwrad1809 Jan 28, 2013 7:30 PM Flag

    I have a REAL question about catalyst that Im hoping someone can ...

    ... give me an honest answer about. I see in the recent coverage that Cowen estimates approval in 2016. Does that sound right? Am I misunderstanding something. I thought there was some chance of early approval this quarter. Please clarify. Thanks in advance.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Cowen is looking longer term and saying without AA (which I think AA is a lock) the stock will still be a big gainer. This is one of those rare biotech situations where even if SRPT doesn't get AA (again I think they will) the company still has a great future. The stock "will" go down in the short run which will provide a good opportunity for longer-term investor, like me, to pick up shares on the cheap. AA or no AA SRPT has great management and a great future....you'll just get your first payday quicker with AA.

    • It's clear that niward is a short in panic.

      Sentiment: Strong Buy

    • Early approval yes. This quarter no. What will happen this Q is the team will visit with FDA for a end of phase II meeting, and on the agenda will be a discussion of using the current data to apply for Accelerated approval (AA). If the FDA likes the data and the plans for manufacturing etc, they will 'invite' SRPT to apply for AA. This is gong to be seen as a liely approval nod, even though they have yet to formally apply. Some time after the meeting SRPT will tell the arket what the FDA meeting was all about. That is the catalyst, the advice they get from FDA. Later in the year SRPT will then announce that they have indeed filed, and some time less than 6 months after that FDA will give thunmbs up or down on AA. If they give a thumbs down, it doesn't mean a failure it means they will have to do a ph3 trial and then apply for market approval via standard approach. The copany still makes sense for investing either way, the question is how soo to the big payday for investors. If they (FDA) give a nod to an AA application, then there are three big inflection points this year. 1) When FDA gives nod 2) When SRPT announces they applied for AA and 3) When FDA takes a record of

 
SRPT
13.42+0.21(+1.59%)Dec 22 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.